Nectar Lifesciences update: litigations, AGM dates 2026

Key AGM and book closure dates

Nectar Lifesciences Limited has scheduled its 31st Annual General Meeting (AGM) for September 18, 2026, for the financial year 2025-26. The company also disclosed the book closure window for the same. The book closure is set from September 12, 2026 to September 18, 2026, with both days included. These dates matter for shareholders tracking eligibility for participation and related corporate actions tied to the AGM. The AGM notice is part of the company’s routine compliance and governance calendar for the year.

Income tax matter for AY 2017-18 ends with NIL impact

The company informed stock exchanges that it received a favourable order from the Deputy Commissioner of Income Tax (DCIT), Chandigarh. The order disposes of the assessment matter for Assessment Year 2017-18. Nectar Lifesciences stated that the outcome has no financial implications for the company. In its disclosure, the quantum of claims related to this order was indicated as NIL. This order closes the last piece of a multi-year income tax dispute that covered multiple assessment years.

How the multi-year tax litigation unfolded

The litigation began with challenges to income tax notices issued under Sections 148 and 148A(b) of the Income Tax Act, 1961. These notices covered Assessment Years 2017-18 to 2021-22. Nectar Lifesciences filed a writ petition before the Punjab and Haryana High Court. The High Court directed the Income Tax Department to dispose of the company’s objections within eight weeks, as disclosed by the company. Nectar Lifesciences also noted that it had received favourable orders in May 2025 for other assessment years involved in the dispute. With the AY 2017-18 matter now disposed of, the company said the entire issue stands fully concluded across all contested years.

Timeline: order date and receipt date

Nectar Lifesciences disclosed specific dates around the final order. The DCIT, Central Circle-1, Chandigarh issued the order for AY 2017-18 on March 31, 2026. The company said it received the order through email on April 9, 2026. The disclosure emphasised that there is no expected financial impact from this decision. For investors, the clarity on dates helps establish when the matter formally ended and when the company became aware of it.

Mumbai civil court case returned, no liability recorded

Separately, the company reported a favourable outcome in litigation before the Mumbai City Civil Commercial Court. The plaint filed by Sanjay Chemicals India Private Limited was returned by the court on March 7, 2026, according to the company’s update. The plaintiff had sought recovery of ₹43,30,914 as principal amount, along with 21% interest and a ₹2,00,000 penalty. Nectar Lifesciences said it successfully argued that the court lacked jurisdiction and that the claims were time-barred. The suit stands disposed of, with no financial liability or action against the company, as per the disclosure.

CGST writ petition creates fresh exposure, hearing set for April 28, 2026

Nectar Lifesciences also disclosed a new litigation development involving indirect taxes. The Principal Commissioner of CGST Commissionerate, Ludhiana filed a civil writ petition before the Punjab and Haryana High Court. The petition challenges an appellate order passed by the Commissioner (Appeal) in May 2025 that was favourable to the company on major portions of the demand. As disclosed, the appellate order upheld a demand of ₹17.06 lakh in ineligible Input Tax Credit (ITC) and imposed an equal penalty. At the same time, it deleted a balance demand of ₹89.32 crore along with associated interest and penalties, and remanded an issue involving a ₹6.24 crore demand for fresh consideration by the proper officer.

What the company has said on the CGST litigation

In its communication, Nectar Lifesciences said it does not agree with the issues raised in the writ petition. The company stated it would file an appropriate response before the High Court. The matter is scheduled for hearing on April 28, 2026. The company also indicated that it reserved the right to prefer an appeal before the Supreme Court if required. These statements outline the company’s intention to contest the petition through available legal remedies.

Other disclosed corporate actions and business updates

The company disclosed that it extended the completion date for the slump sale of its Empty Hard Gelatin Capsule business to July 31, 2026. It also referenced a dated corporate update pointing to “Q2 FY 25-26 Results” with the date listed as November 14, 2025 (Friday). In another update, Nectar Lifesciences concluded a postal ballot process where shareholders approved three key resolutions. The approvals included the appointment of Mr. Sushil Kapoor as Director and Wholetime Director (Finance) with a monthly salary of ₹3,00,000, and amendments to the Memorandum of Association (MOA). Alongside these corporate items, the company’s business description in the provided material references active pharmaceutical ingredients (APIs), intermediates, and finished dosage, including products such as cephalosporins.

Summary table: key disclosures and quantified amounts

Market impact: what changes and what remains open

From a disclosure standpoint, the income tax litigation conclusion reduces uncertainty because the company explicitly stated there are no financial implications and the quantum is NIL. The Mumbai court matter also ends without a stated liability, after the plaint was returned due to jurisdiction and limitation arguments. However, the CGST writ petition keeps a material tax dispute active because it challenges a prior appellate relief that had dropped ₹89.32 crore in demand and also involves a ₹6.24 crore item remanded for fresh adjudication. The confirmed component in the appellate order, as disclosed, remains ₹17.06 lakh of ineligible ITC plus an equal penalty. The next formal checkpoint for this indirect tax dispute is the April 28, 2026 hearing date disclosed by the company.

Why these updates matter for tracking governance and risk

For shareholders, the set AGM and book closure dates provide clarity on the company’s near-term corporate calendar. The closure of a multi-year income tax matter, with a stated NIL claim quantum, removes one long-running overhang. The Mumbai civil case outcome indicates the company’s success in contesting recovery proceedings on procedural grounds, based on the disclosed reasons. At the same time, the CGST writ petition highlights that the company still faces litigation risk where the outcome could affect the previously dropped demand, interest, and penalties, as the company itself has estimated. The company’s stated plan to file a response and, if needed, pursue higher appellate remedies suggests the dispute may continue beyond the next hearing.

Conclusion

Nectar Lifesciences has combined routine corporate updates, including its September 2026 AGM schedule, with several litigation disclosures. The income tax dispute for AY 2017-18 has been disposed of with NIL financial implication, and a Mumbai civil suit has been disposed of with no stated liability. The key unresolved item is the CGST writ petition, where the next hearing is scheduled for April 28, 2026. Investors will likely track developments around that hearing and the company’s response filings, along with the July 31, 2026 timeline for the capsule business slump sale completion.